Biogen Inc (BIIB)

$167.55 +2.82 (1.71%)
Market Cap 24.58B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 9.84
Forward PE 11.05
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 2,620,800
Avg Vol 1,747,478
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 93%
Beta 0.10
Analysts Sell
Price Target $176.07

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
SchwallerCapital
SchwallerCapital Nov. 16 at 3:59 AM
$BIIB this has been amazing. Making up for all of the pain we’ve been through for a while now
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 10:35 PM
$BIIB: The last close at $167.55 indicates a strong position, but the RSI at 74.74 suggests it is overbought, indicating potential for a pullback. The MA30 at 151.34 and MA50 at 148.37 show a bullish trend, yet the distance from these moving averages highlights the risk of a correction. The recent 60D high of 169.0 is a key resistance level, while the 60D low of 131.52 provides a solid support reference. Directional bias is cautiously bearish in the short term due to the overbought RSI, despite the overall bullish trend indicated by the MAs. Suggested entry: Consider entering a short position around $167.50. Stop loss: $170.00 to manage risk above the recent high. Targets: $162.00 for a first target, and $158.00 for a second target, aligning with the bullish MAs and providing a safer exit if the pullback occurs. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 15 at 6:33 PM
$BIIB $IFRX Cont: If my theory is correct on this, part 1 will be reveal Tuesday Nov 25 when short data is released by nasdaq for the period ending 11/14/25. If that shows 10m short, this theory get validated moreso. Since some will claim Inflarx was the seller via ATM, I’ll remind you SEC rules prohibit selling ATM in pre/ post market where most of volume occurred- and this is just 1 of many restrictive rules on ATM. So what’s it mean (of theory holds up)? If Inflarx decides to fund via partner and not do a secondary (very soon) - we cld see a 10m share buyer emerge with no source of artificial supply. Lower volume move up would support this - but expect them to defend position. A few new funds like B of A taking 2.5m each shares wld expedite cover. It’s only reason we’re not at $4 today imo. Watch Nov 25
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:32 AM
$BIIB: The last close at $167.55 indicates a strong position, but the RSI at 74.74 suggests it is overbought, indicating potential for a pullback. The MA30 at 151.34 and MA50 at 148.37 show a bullish trend, yet the distance from these moving averages highlights the risk of a correction. The recent 60D high of 169.0 is a key resistance level, while the 60D low of 131.52 provides a solid support reference. Directional bias is cautiously bearish in the short term due to the overbought RSI, despite the overall bullish trend indicated by the MAs. Suggested entry: Consider entering a short position around $167.50. Stop loss: $170.00 to manage risk above the recent high. Targets: $162.00 for a first target, and $158.00 for a second target, aligning with the bullish MAs and providing a safer exit if the pullback occurs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:53 PM
$BIIB is currently trading at $167.55, showing a strong upward momentum with an RSI of 74.74, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of 151.34 and the 50-day moving average (MA50) of 148.37, suggesting a bullish trend. However, the high of $169.00 within the last 60 days presents a resistance level, while the low of $131.52 indicates significant support. Given the overbought RSI, a pullback could occur, making it prudent to wait for a slight dip. Suggested entry is around $165.00, with a stop loss at $162.00 to manage risk. Target 1 is set at $170.00, aligning with the 60D high, while Target 2 is at $172.00, allowing for further upside potential if momentum continues. Overall, the analysis suggests a bullish bias, but caution is warranted due to the current RSI level. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 14 at 11:07 PM
$IFRX OPEN AI : Based on recent licensing deals, a Phase 2 asset like InflaRx's INF904 would have a much higher valuation range than $BIIB / Vanqua's preclinical asset, typically seeing significantly larger upfront payments and total potential deal values. Potential "Fair Value" for InflaRx If a large pharmaceutical company were to license InflaRx's P2 asset (INF904), the market data suggests a "fair value" based on the following: Upfront Payment Range: $775 million -$1 billion Total Deal Value: The entire deal, including all potential development, regulatory, and sales milestones, could easily reach several billion dollars, often between $1.5 billion and $3 billion, depending on the specific disease area, market potential, and data strength. De-risking: A Phase 2 asset is considered significantly less risky than a preclinical one, as it has already shown initial safety and efficacy in humans. This stage of development commands a higher valuation from potential partners.
3 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 14 at 4:08 PM
$BIIB RSI: 74.74, MACD: 4.1393 Vol: 5.81, MA20: 152.28, MA50: 147.87 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_Verticality
_Verticality Nov. 14 at 10:25 AM
Breaking out!? How much volume do you think it takes to gap ARBB up? ARBB has not even 700K shares float and recent news. Hoping for a 100% run on ARBB $AMCR $BIIB $KEP $NYT :
0 · Reply
_Verticality
_Verticality Nov. 14 at 8:24 AM
$STM $INTS $BIIB $SOC +
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 4:28 AM
options heat check $ASTS $BIIB $FLR $LYFT $WYNN all lighting up the tape with sneaky whale moves today https://stocksrunner.com/news/2025-11-13-unusual-options-activity-signal-moves-ahead
0 · Reply
Latest News on BIIB
Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 1 day ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

Nov 13, 2025, 6:41 PM EST - 2 days ago

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Nov 13, 2025, 6:30 PM EST - 2 days ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Nov 10, 2025, 5:01 PM EST - 5 days ago

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Nov 3, 2025, 7:30 AM EST - 12 days ago

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 16 days ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 7:40 AM EDT - 16 days ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 30, 2025, 6:11 AM EDT - 16 days ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 26, 2025, 7:30 PM EDT - 20 days ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 8:30 AM EDT - 22 days ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Oct 24, 2025, 7:30 AM EDT - 22 days ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Oct 22, 2025, 7:30 AM EDT - 24 days ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Oct 13, 2025, 7:30 PM EDT - 4 weeks ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 5 weeks ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 5 weeks ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

STOK

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 5 weeks ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Oct 6, 2025, 4:30 PM EDT - 5 weeks ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BMY GILD

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 6 weeks ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

‘Fast Money' traders talk opportunities in health care stocks

Oct 1, 2025, 5:48 PM EDT - 6 weeks ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BMY IBB LLY MRK MRNA PFE

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Sep 28, 2025, 7:30 PM EDT - 6 weeks ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

Sep 26, 2025, 12:21 PM EDT - 7 weeks ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BMY

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 2:17 PM EDT - 7 weeks ago

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

Sep 24, 2025, 7:30 AM EDT - 7 weeks ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

US FDA declines to approve higher-dose of Biogen's genetic disorder drug

Sep 23, 2025, 4:41 PM EDT - 7 weeks ago

US FDA declines to approve higher-dose of Biogen's genetic disorder drug

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Sep 23, 2025, 4:30 PM EDT - 7 weeks ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Sep 18, 2025, 7:40 AM EDT - 2 months ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Sep 17, 2025, 4:30 PM EDT - 2 months ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 6:51 PM EDT - 2 months ago

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD JNJ LLY MRK

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Sep 2, 2025, 7:30 PM EDT - 2 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

STOK

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Sep 2, 2025, 4:54 AM EDT - 2 months ago

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

NIO NVDA

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

Aug 29, 2025, 5:08 PM EDT - 2 months ago

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Aug 29, 2025, 5:00 PM EDT - 2 months ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Aug 28, 2025, 2:16 PM EDT - 2 months ago

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

STOK

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Aug 25, 2025, 3:00 AM EDT - 2 months ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

STOK

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Aug 2, 2025, 9:15 AM EDT - 3 months ago

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 2:24 PM EDT - 3 months ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Biogen raises annual profit forecast on strong demand for rare disease drugs

Jul 31, 2025, 6:17 AM EDT - 3 months ago

Biogen raises annual profit forecast on strong demand for rare disease drugs

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Jul 30, 2025, 11:00 AM EDT - 3 months ago

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Jul 30, 2025, 8:12 AM EDT - 3 months ago

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

SchwallerCapital
SchwallerCapital Nov. 16 at 3:59 AM
$BIIB this has been amazing. Making up for all of the pain we’ve been through for a while now
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 10:35 PM
$BIIB: The last close at $167.55 indicates a strong position, but the RSI at 74.74 suggests it is overbought, indicating potential for a pullback. The MA30 at 151.34 and MA50 at 148.37 show a bullish trend, yet the distance from these moving averages highlights the risk of a correction. The recent 60D high of 169.0 is a key resistance level, while the 60D low of 131.52 provides a solid support reference. Directional bias is cautiously bearish in the short term due to the overbought RSI, despite the overall bullish trend indicated by the MAs. Suggested entry: Consider entering a short position around $167.50. Stop loss: $170.00 to manage risk above the recent high. Targets: $162.00 for a first target, and $158.00 for a second target, aligning with the bullish MAs and providing a safer exit if the pullback occurs. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 15 at 6:33 PM
$BIIB $IFRX Cont: If my theory is correct on this, part 1 will be reveal Tuesday Nov 25 when short data is released by nasdaq for the period ending 11/14/25. If that shows 10m short, this theory get validated moreso. Since some will claim Inflarx was the seller via ATM, I’ll remind you SEC rules prohibit selling ATM in pre/ post market where most of volume occurred- and this is just 1 of many restrictive rules on ATM. So what’s it mean (of theory holds up)? If Inflarx decides to fund via partner and not do a secondary (very soon) - we cld see a 10m share buyer emerge with no source of artificial supply. Lower volume move up would support this - but expect them to defend position. A few new funds like B of A taking 2.5m each shares wld expedite cover. It’s only reason we’re not at $4 today imo. Watch Nov 25
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:32 AM
$BIIB: The last close at $167.55 indicates a strong position, but the RSI at 74.74 suggests it is overbought, indicating potential for a pullback. The MA30 at 151.34 and MA50 at 148.37 show a bullish trend, yet the distance from these moving averages highlights the risk of a correction. The recent 60D high of 169.0 is a key resistance level, while the 60D low of 131.52 provides a solid support reference. Directional bias is cautiously bearish in the short term due to the overbought RSI, despite the overall bullish trend indicated by the MAs. Suggested entry: Consider entering a short position around $167.50. Stop loss: $170.00 to manage risk above the recent high. Targets: $162.00 for a first target, and $158.00 for a second target, aligning with the bullish MAs and providing a safer exit if the pullback occurs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:53 PM
$BIIB is currently trading at $167.55, showing a strong upward momentum with an RSI of 74.74, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of 151.34 and the 50-day moving average (MA50) of 148.37, suggesting a bullish trend. However, the high of $169.00 within the last 60 days presents a resistance level, while the low of $131.52 indicates significant support. Given the overbought RSI, a pullback could occur, making it prudent to wait for a slight dip. Suggested entry is around $165.00, with a stop loss at $162.00 to manage risk. Target 1 is set at $170.00, aligning with the 60D high, while Target 2 is at $172.00, allowing for further upside potential if momentum continues. Overall, the analysis suggests a bullish bias, but caution is warranted due to the current RSI level. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 14 at 11:07 PM
$IFRX OPEN AI : Based on recent licensing deals, a Phase 2 asset like InflaRx's INF904 would have a much higher valuation range than $BIIB / Vanqua's preclinical asset, typically seeing significantly larger upfront payments and total potential deal values. Potential "Fair Value" for InflaRx If a large pharmaceutical company were to license InflaRx's P2 asset (INF904), the market data suggests a "fair value" based on the following: Upfront Payment Range: $775 million -$1 billion Total Deal Value: The entire deal, including all potential development, regulatory, and sales milestones, could easily reach several billion dollars, often between $1.5 billion and $3 billion, depending on the specific disease area, market potential, and data strength. De-risking: A Phase 2 asset is considered significantly less risky than a preclinical one, as it has already shown initial safety and efficacy in humans. This stage of development commands a higher valuation from potential partners.
3 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 14 at 4:08 PM
$BIIB RSI: 74.74, MACD: 4.1393 Vol: 5.81, MA20: 152.28, MA50: 147.87 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
_Verticality
_Verticality Nov. 14 at 10:25 AM
Breaking out!? How much volume do you think it takes to gap ARBB up? ARBB has not even 700K shares float and recent news. Hoping for a 100% run on ARBB $AMCR $BIIB $KEP $NYT :
0 · Reply
_Verticality
_Verticality Nov. 14 at 8:24 AM
$STM $INTS $BIIB $SOC +
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 4:28 AM
options heat check $ASTS $BIIB $FLR $LYFT $WYNN all lighting up the tape with sneaky whale moves today https://stocksrunner.com/news/2025-11-13-unusual-options-activity-signal-moves-ahead
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:27 AM
$BIIB is currently trading at $164.73, showing a strong upward momentum but with an RSI of 72.96, indicating it is in overbought territory. The price is above both the 30-day MA of 151.08 and the 50-day MA of 147.83, suggesting bullish sentiment in the short term. However, the proximity to the 60-day high of 167.87 raises caution for potential pullbacks. Directional bias is bullish, but with the RSI indicating overbought conditions, a correction may occur. Suggested entry point: $163.50, allowing for a slight pullback. Stop loss at $159.00 to manage risk. Targets: First target at $168.00 (near 60D high), and a second target at $170.00, considering potential breakout momentum. Monitor closely for signs of reversal or continuation as the price approaches these targets. https://privateprofiteers.com
0 · Reply
esquire_f14
esquire_f14 Nov. 13 at 10:54 PM
$BIIB greeen in a red market 😍
0 · Reply
rklyons
rklyons Nov. 13 at 8:15 PM
$BIIB any news for investors during this summit?
0 · Reply
TalkMarkets
TalkMarkets Nov. 13 at 5:29 PM
#Dow Cools From Record; #Nasdaq Swimming In Red Ink $BIIB $CSCO $SPX $VIX $HOOD https://talkmarkets.com/content/us-markets/dow-cools-from-record-nasdaq-swimming-in-red-ink?post=536901
0 · Reply
Albino_Trader123
Albino_Trader123 Nov. 13 at 3:06 PM
$REGN $BIIB $GILD $LLY $AMGN Nice to see green when techs are plummeting. Been hiding in these names past 2 weeks paying out
0 · Reply
rklyons
rklyons Nov. 13 at 3:05 PM
$BIIB cmon pump baby pump
0 · Reply
Chartist0_0
Chartist0_0 Nov. 13 at 2:40 PM
$BIIB 235$ by St. Paddy's day
0 · Reply
DenchDaddy
DenchDaddy Nov. 13 at 1:18 PM
$BIIB question is - is pharma back on the table ? $MRK $PFE $MRNA
0 · Reply
testius
testius Nov. 13 at 10:36 AM
$IFRX Biogen $BIIB could still acquire INF904 in nefrology, Biogen already showed interest in that indication, while Inflarx hinted to it too.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:34 AM
$BIIB: The last close at $159.39 indicates a strong position within the recent trading range, with the 60D high at $160.2 acting as a resistance level. The RSI at 69.76 suggests that the stock is approaching overbought territory, which may lead to a pullback. However, the stock remains above both the 30-day MA of $150.52 and the 50-day MA of $146.93, indicating a bullish trend in the medium term. Directional bias is cautiously bullish, but with an awareness of potential short-term corrections due to the elevated RSI. Suggested entry is at $158.00 to capitalize on potential upward momentum. Set a stop loss at $155.00 to manage risk. Target 1 is $162.00, just above the 60D high, and Target 2 is $165.00, allowing for further gains if the bullish trend continues. Monitor market conditions closely, as a reversal could occur if the RSI declines significantly. https://privateprofiteers.com
0 · Reply
Chingying
Chingying Nov. 12 at 9:47 PM
$BIIB To $171 before pullback.
0 · Reply
doctordinero
doctordinero Nov. 12 at 4:49 PM
$GILD Was in the 60s for about 10 years and then off it went. Patience is king. $BIIB and $BMRN next. GLTA. $SPY
1 · Reply